Clinical trial
Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD…
NCT00471094 · Takeda, Industry · Completed
Key facts
| NCT number | NCT00471094 |
|---|---|
| Title | Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis |
| Official title | A Phase 2 Study to Evaluate the Safety and Efficacy of Ilaprazole (5 mg QD, 20 mg QD and 40 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis. |
| Lead sponsor | Takeda, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophagitis |
| Intervention type | Drug |
| Interventions | Ilaprazole, Lansoprazole |
| Enrollment | 831 |
| Start date | May 1, 2007 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | May 9, 2007 |
| Last update posted | Feb 2, 2012 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: